Ginkgo Bioworks put $80 million into Synlogic (NSDQ:SYBX) last week in a deal to use its cell programming technology to accelerate development of Synlogic’s synthetic biotic medicine program. Boston-based Gingko acquired some 6.3 million SYBX shares and warrants for another 2.5 million shares at $9 apiece; Synlogic then paid $30.0 million back to Gingko for […]
synlogic
Synlogic finalizes Mirna Therapeutics merger
Synlogic said today that it finished its merger with Mirna Therapeutics after the deal won approval from Mirna’s stockholders last week. The merged company, which will trade on the Nasdaq market under the symbol “SYBX”, is slated to advance Synlogic’s Synthetic Biotic medicines. The company’s platform uses synthetic biology to reprogram probiotic bacteria to treat […]
